Vaxcyte Announces Pricing of $1.3 Billion Public Offering
SAN CARLOS, Calif., Sept. 04, 2024 ( GLOBE NEWSWIRE ) -- Vaxcyte, Inc. ( Nasdaq: PCVX ) , a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public ...
| Ticker |
Sentiment |
Impact |
|
EVR
|
Neutral
|
9 %
|
|
PCVX
|
Somewhat Bullish
|
40 %
|
|
STRO
|
Neutral
|
5 %
|
|
STT
|
Neutral
|
5 %
|
|
GS
|
Neutral
|
9 %
|
